Compounds > n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine
Page last updated: 2024-09-03

n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine and CJD (Creutzfeldt-Jakob Disease)

n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine has been researched along with CJD (Creutzfeldt-Jakob Disease) in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Clark, DB; Coupal, JJ; DeKosky, ST; DeLand, FH; Domstad, PA; Goldstein, S; Kung, H; Markesbery, WR; Shih, WJ1

Other Studies

1 other study(ies) available for n,n,n'-trimethyl-n'-(2-hydroxy-3-methyl-5-iodobenzyl)-1,3-propanediamine and CJD (Creutzfeldt-Jakob Disease)

ArticleYear
Iodine-123 HIPDM brain imaging findings in subacute spongiform encephalopathy (Creutzfeldt-Jakob disease).
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1987, Volume: 28, Issue:9

    Topics: Aged; Brain; Creutzfeldt-Jakob Syndrome; Humans; Iodobenzenes; Male; Radionuclide Imaging

1987